Evidence map›Paper›PMID 40607476›Full record

ArticleIJU case reports2025

Enfortumab Vedotin-Induced Toxic Epidermal Necrolysis in Metastatic Urothelial Carcinoma Complicated by Severe Gastrointestinal Bleeding.

Aika Matsuyama, Takashi Kato, Rion Kawase, Mikinori Kobayashi, Ayako Momota, Yukiko Tsunoda, Asaomi Yamaguchi, Hiroki Hirabayashi, Shoji Suzuki, Masashi Kato

Abstract read
In one paragraph

Article in IJU case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Aika MatsuyamaDepartment of Urology Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital Nagoya Japan.ORCID https://orcid.org/0000-0002-5595-9046
Takashi KatoDepartment of Urology Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital Nagoya Japan.
Rion KawaseDepartment of Urology Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital Nagoya Japan.
Mikinori KobayashiDepartment of Urology Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital Nagoya Japan.
Ayako MomotaDepartment of Urology Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital Nagoya Japan.
Yukiko TsunodaDepartment of Female Urology Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital Nagoya Japan.
Asaomi YamaguchiDepartment of Urology Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital Nagoya Japan.
Hiroki HirabayashiDepartment of Urology Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital Nagoya Japan.
Shoji SuzukiDepartment of Female Urology Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital Nagoya Japan.
Masashi KatoDepartment of Urology Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital Nagoya Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Enfortumab vedotin (EV) has been reported to cause skin toxicity in some patients. We report a rare case of toxic epidermal necrolysis (TEN) induced by EV and complicated by severe gastrointestinal (GI) bleeding. Case Presentation: A 70-year-old man with recurrent urothelial carcinoma developed a trunk rash at 16 days after EV administration. He presented to the emergency department with loss of consciousness and was diagnosed with TEN and septic shock. Although pulse steroid therapy improved his skin lesions, his abdominal symptoms progressively worsened. On Day 27, he developed massive GI bleeding. Despite intensive interventions, he died of multiple organ failure on Day 30. Conclusion: This case highlights that Stevens-Johnson syndrome/TEN induced by EV can develop shortly after treatment, with delayed and potentially fatal GI manifestations. Given the challenges in managing established TEN, close monitoring for adverse events is essential.

Indexed as

enfortumab vedotingastrointestinal bleedingtoxic epidermal necrolysisurothelial carcinoma

Identifiers

PMID40607476
PMCPMC12212949

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.